FORUM · Institut für Management GmbH
Vangerowstraße 18
69115 Heidelberg
Telefon: +49 6221 500-500
Fax: +49 6221 500-505

HTA Assessment in Germany,
Spain, the UK and the EU

2017-09-29 2017-09-29 Mercure Hotel MOA Berlin Stephanstr. 41 10559 Berlin +49 30 394043-0 +49 30 394043-999

HTA Assessment in Germany, Spain, the UK and the EU

National HTA systems, pricing and harmonisation efforts from Joint Action 3

This conference provides thorough insights into the national procedures in Germany, Spain, the UK and Ireland.


  • Evidence generation - Harmonised early advice in Europe? Jointly produced European HTAs?
  • Real-World Evidence and authorities' acceptance
  • Medicines evaluation in Germany, Spain, the UK and Ireland
  • Early access possibilities in Europe
  • From HTA to pricing

This distinguishes our event

Overall impression: 89 % of the participants' feedback was very good or good (September 2016)

Aims and objectives

HTA/value assessment is an essential tool in many national European healthcare systems.

This conference provides thorough insights into the national procedures in Germany, Spain, the UK and Ireland. It also provides a sound update on European harmonisation efforts in terms of harmonised early advice or joint HTAs.

Early access availability, pricing and pricing strategies will round off the conference, enabling you to optimise your market access strategy for the various European markets.

Who should attend?

This conference addresses the needs of employees in the pharmaceutical industry responsible for market access activities in the various national European markets.

Those involved in value-assessment preparation and pricing activities will benefit particularly from this conference.

Your speakers

Dr. Alexander Natz
EUCOPE - European Confederation of Pharmaceutical Entrepreneurs, Brüssel, Belgien

Your speakers of day one
Dr. Hannah Brühl
Federal Joint Committee, Berlin, GERMANY

Dirk Eheberg
QuintilesIMS, München

Mag. rer. nat. Sabine Ettinger, MSc
Ludwig Boltzmann Institute für Health Technology Assessment, Vienna, AUSTRIA

Dr. François Meyer
French National Authority for Health (HAS), FRANCE

Thomas Müller
Federal Joint Committee (G-BA), Berlin, GERMANY

Your speakers of day two
Dr. Antoni Gilabert
Catalan Health and Social Care Consortium (CSC), Barcelona, SPAIN

Christian Hill
MAP BioPharma, Cambridge, GREAT BRITAIN

Andrew Gapper
MAP BioPharma Limited, Papworth Everard, Cambridge, GREAT BRITAIN

Go forward

Our international course portfolio

Are you interested in our international continuous education programme? We provide a variety of specialised courses.


Jahrestagung - Pharma Trends

Die 37. Gesundheitspolitische Jahrestagung - Pharma Trends - bringt die Entscheider des GKV-Systems zusammen. Diskutieren Sie mit Vortragenden aus Politik, G-BA, GKV, Industrie und Ärzteschaft über die aktuellen Aufgabestellungen nach Abschluss des Pharma-Dialogs.


Quality guaranteed!

IMI (Innovative Medicines Initiative) defined quality criteria for professional training and education. We follow these criteria and, as a signatory, we are an active partner in further developing and optimising the quality standards. An aggregate evaluation of participants' feedback on all FORUM's healthcare training courses (evaluation period from 10.2014 - 09.2015) produced a result of 1.7 (based on a school grading system of 1-6).